Overview of Acute Myeloid Leukemia

By Jorge E. Cortes, MD
Brian Andrew Jonas, MD, PhD
Hetty Carraway, MD
Margaret T. Kasner, MD

Opening their discussion on the management of acute myeloid leukemia (AML), expert oncologists provide an overview on the incidence, diagnosis, and stratification of patients.

Related Videos
View All
Related Content

European Commission to Review Luspatercept for Anemia-Associated, Non-Transfusion Dependent Beta Thalassemia

January 27th 2023

Lunning Lends Insight on Pivotal Data From Pan Pacific Lymphoma 2022

November 10th 2022

Pembrolizumab Following ASCT Generates Promising PFS in T-cell Non-Hodgkin Lymphoma

January 23rd 2023

Sauter and Hill Talk Through CAR T-Cell Sequencing and Access in Lymphomas

November 7th 2022

Ibrutinib/Prednisone Provides No CR/PR Benefit vs Placebo/Prednisone in cGVHD

January 18th 2023

NCCN Adds Olutasidenib to Guidelines for Relapsed/Refractory, IDH1-Mutant AML

January 18th 2023

European Commission to Review Luspatercept for Anemia-Associated, Non-Transfusion Dependent Beta Thalassemia

January 27th 2023

Lunning Lends Insight on Pivotal Data From Pan Pacific Lymphoma 2022

November 10th 2022

Pembrolizumab Following ASCT Generates Promising PFS in T-cell Non-Hodgkin Lymphoma

January 23rd 2023

Sauter and Hill Talk Through CAR T-Cell Sequencing and Access in Lymphomas

November 7th 2022

Ibrutinib/Prednisone Provides No CR/PR Benefit vs Placebo/Prednisone in cGVHD

January 18th 2023

NCCN Adds Olutasidenib to Guidelines for Relapsed/Refractory, IDH1-Mutant AML

January 18th 2023

European Commission to Review Luspatercept for Anemia-Associated, Non-Transfusion Dependent Beta Thalassemia

January 27th 2023

Lunning Lends Insight on Pivotal Data From Pan Pacific Lymphoma 2022

November 10th 2022

Pembrolizumab Following ASCT Generates Promising PFS in T-cell Non-Hodgkin Lymphoma

January 23rd 2023

Sauter and Hill Talk Through CAR T-Cell Sequencing and Access in Lymphomas

November 7th 2022

Ibrutinib/Prednisone Provides No CR/PR Benefit vs Placebo/Prednisone in cGVHD

January 18th 2023

NCCN Adds Olutasidenib to Guidelines for Relapsed/Refractory, IDH1-Mutant AML

January 18th 2023
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact